More than half of all patients with advanced urothelial cancer cannot receive standard, first-line cisplatin-based chemotherapy because of renal dysfunction, poor performance status, or other comorbidities. We assessed the activity and safety of first-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer.

中文翻译：

---

一线Pembrolizumab用于不符合顺铂治疗，局部晚期且不可切除或转移性尿路上皮癌的患者（KEYNOTE-052）：一项多中心，单组，2期研究。

在所有晚期尿路上皮癌患者中，超过一半的患者由于肾功能不全，表现不佳或其他合并症而无法接受基于顺铂一线的标准一线化疗。我们评估了不符合顺铂治疗的局部晚期，不可切除或转移性尿路上皮癌患者中一线pembrolizumab的活性和安全性。